1003711-13-4 Usage
General Description
2-AMINO-5-CYANO-3-NITROPYRIDINE is a chemical compound with the molecular formula C6H4N4O2. It is a pyridine derivative that contains an amino group, a cyano group, and a nitro group. It is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. The compound has potential applications in the field of medicinal chemistry, as it can serve as a building block for the development of new drugs. 2-AMINO-5-CYANO-3-NITROPYRIDINE is also utilized in the production of dyes, pigments, and other organic compounds. It is important to handle this chemical with care, as it may pose health and environmental risks if not properly managed.
Check Digit Verification of cas no
The CAS Registry Mumber 1003711-13-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,3,7,1 and 1 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1003711-13:
(9*1)+(8*0)+(7*0)+(6*3)+(5*7)+(4*1)+(3*1)+(2*1)+(1*3)=74
74 % 10 = 4
So 1003711-13-4 is a valid CAS Registry Number.
1003711-13-4Relevant articles and documents
COMPOSITIONS AND METHODS FOR INHIBITING CD73
-
Paragraph 0357, (2019/12/25)
Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.
Novel non-benzimidazole chk2 kinase inhibitors
McClure, Kelly J.,Huang, Liming,Arienti, Kristen L.,Axe, Frank U.,Brunmark, Anders,Blevitt, Jon,Guy Breitenbucher
, p. 1924 - 1928 (2007/10/03)
In a recent paper, [Arienti, K. L.; Brunmark, A.; Axe, F. U.; McClure, K. M.; Lee, A.; Blevitt, J.; Neff, D. K.; Huang, L.; Crawford, S.; Chennagiri, R. P.; Karlsson, L.; Brietenbucher, J. G. J. Med. Chem. 2005, 48, 1873], we described the discovery of a class of benzimidazole chk2 kinase inhibitors, exemplified by compound 1, which had radio-protective effects in human T-cells subjected to ionizing radiation. Here, a series of non-benzimidazole analogs intended to define the scope of the SAR about this new series of inhibitor, and allow for refinement of the binding model of these compounds to the chk2 kinase is described.
